Beone Medicines Ltd (stock code: 06160) has released its financial results for the second quarter of fiscal year 2026, showcasing robust performance. For the second quarter, the company's global total revenue reached approximately $1.705 billion, marking a 30% year-over-year increase. GAAP net income stood at roughly $237 million, up 151% from the same period last year, while adjusted net income was about $444 million, representing a 76% growth.
Product revenue for the second quarter of 2026 totaled $1.7 billion, reflecting a 29% increase from the prior year. BeiGene's lead drug, Zanubrutinib (marketed as BRUKINSA), generated global sales of $1.2 billion in the second quarter, up 31% compared to the same period in 2025. In the United States, Zanubrutinib sales reached $893 million, also a 31% rise. Tislelizumab (marketed as TEVIMBRA/JZP) achieved global sales of $229 million in the second quarter, an 18% growth. Sales from products licensed from Amgen amounted to $157 million for the quarter, a 25% increase.
For the first half of 2026, total revenue was $3.2185 billion, a 32% jump from the prior year. GAAP net income for the half-year period was approximately $464 million, surging 386% year-over-year. Adjusted net income reached about $819.5 million, representing a 111% increase.
John Oyler, co-founder, chairman, and CEO of Beone Medicines, commented, "The strong performance in the second quarter once again underscores our continued growth momentum as a global leader in oncology treatment. Our core hematology business, led by Zanubrutinib, maintains strong momentum, while we are advancing one of the industry's most diverse and deep research and development pipelines. With differentiated capabilities spanning drug discovery, clinical development, manufacturing, and commercialization, we are well-prepared for the next phase of global growth."
Looking ahead, Beone Medicines has provided its full-year 2026 revenue guidance, projecting total revenue between $6.6 billion and $6.8 billion. This forecast includes strong growth expectations driven by the leading position of Zanubrutinib in the U.S. market and its continued expansion in Europe and other key global markets. The company expects its gross margin to be in the high 80% range, considering the product mix and efficiency improvements in manufacturing for the full year. Guidance for GAAP operating expenses includes anticipated investments to support future growth. The company projects GAAP operating profit to be between $1 billion and $1.1 billion, with non-GAAP operating profit expected to be between $1.7 billion and $1.8 billion.
Comments